We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

Article
Predicting and Overcoming Resistance Using IsoPlexis’ Single-Cell Intracellular Proteomic and Metabolomic Analysis

Learn how single-cell proteomics has helped researchers overcome resistance to targeted inhibitors, leading to better strategies and combination therapies.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Article we discuss:

Single-cell intracellular proteomics and single-cell metabolomics combine to characterize drug resistance in melanoma cells
Proteomic analysis is instrumental in filling the knowledge gap left by genomics, especially at the single-cell level
Using our proteomic barcoding technology, researchers characterized cellular heterogeneity within cell populations at different timepoints
A Deeper Look

More about this Article

Fully Characterize Cancer Cells with Single-Cell Functional Proteomics

Cancer cells develop resistance to targeted therapies, and researchers are striving to understand and characterize how these cancer cells are adapting to these therapies.

Although cancer cells have been characterized at the genetic and genomic levels, the functional mechanisms impacting protein-driven functional behaviors can only be revealed through IsoPlexis’ Single-Cell Proteomics.

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the Article
Back to the Top